Industry Strength Score
55/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
LEXEO THERAPEUTICS INC (LXEO) Stock Price & Overview
NASDAQ:LXEO • US52886X1072
Current stock price
5.68 USD
-0.13 (-2.24%)
At close:
5.68 USD
0 (0%)
After Hours:
The current stock price of LXEO is 5.68 USD. Today LXEO is down by -2.24%. In the past month the price decreased by -1.05%. In the past year, price increased by 22.41%.
LXEO Key Statistics
52-Week Range2.43 - 10.99
Current LXEO stock price positioned within its 52-week range.
1-Month Range5.48 - 7.015
Current LXEO stock price positioned within its 1-month range.
- Market Cap
- 420.831M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.19
- Dividend Yield
- N/A
LXEO Stock Performance
Today
-2.24%
1 Week
-10.27%
1 Month
-1.05%
3 Months
-23.35%
Longer-term
6 Months -43.26%
1 Year +22.41%
2 Years -54.38%
3 Years N/A
5 Years N/A
10 Years N/A
LXEO Stock Chart
LXEO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LXEO. When comparing the yearly performance of all stocks, LXEO is a bad performer in the overall market: 65.64% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
LXEO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LXEO. LXEO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LXEO Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.27
Revenue Reported
EPS Surprise 15.85%
Revenue Surprise %
LXEO Forecast & Estimates
17 analysts have analysed LXEO and the average price target is 19.99 USD. This implies a price increase of 251.97% is expected in the next year compared to the current price of 5.68.
Analysts
Analysts88.24
Price Target19.99 (251.94%)
EPS Next Y37.4%
Revenue Next YearN/A
LXEO Index Membership
LXEO is currently included in the following stock indexes tracked on ChartMill.
LXEO Financial Highlights
Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -2.19. The EPS increased by 28.9% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-99.96M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.2% | ||
| ROE | -40.52% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%65.38%
Sales Q2Q%N/A
EPS 1Y (TTM)28.9%
Revenue 1Y (TTM)N/A
LXEO Ownership
Ownership
Inst Owners104.14%
Shares74.09M
Float66.76M
Ins Owners0.84%
Short Float %18.88%
Short Ratio13.55
LXEO Industry Overview
LXEO operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
44%
Outperformed 44% of sub-industries
6 Month Rank
31%
Outperformed 31% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.8%
- New Lows
- 3.9%
- Average ROE
- 48.2%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.1
- Average Fwd P/E
- 22.4
- Average Debt/Equity
- 2.1
LXEO Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LXEO
Company Profile
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Company Info
IPO: 2023-11-03
LEXEO THERAPEUTICS INC
345 Park Avenue South, Floor 6
New York City NEW YORK US
Employees: 59
Phone: 12125479879
LEXEO THERAPEUTICS INC / LXEO FAQ
What does LXEO do?
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Can you provide the latest stock price for LEXEO THERAPEUTICS INC?
The current stock price of LXEO is 5.68 USD. The price decreased by -2.24% in the last trading session.
Does LEXEO THERAPEUTICS INC pay dividends?
LXEO does not pay a dividend.
What is the ChartMill rating of LEXEO THERAPEUTICS INC stock?
LXEO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of LEXEO THERAPEUTICS INC (LXEO) based on its PE ratio?
LEXEO THERAPEUTICS INC (LXEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.19).
Can you provide the upcoming earnings date for LEXEO THERAPEUTICS INC?
LEXEO THERAPEUTICS INC (LXEO) will report earnings on 2026-05-07.
Can you provide the ownership details for LXEO stock?
You can find the ownership structure of LEXEO THERAPEUTICS INC (LXEO) on the Ownership tab.